Drug Trial Radar · NCT07933419
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
558
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Nov 15, 2027
Study completion Nov 15, 2029
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5133 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion. The main questions it aims to answer are: * In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5133 combination therapy, and what are the recommended dose(s) for expansion? * In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5133 combination therapy at the selected dose(s) in participants with specific tumor types? Participants will: * Be enrolled in sequential cohorts to receive QLS5133 in combination with other anticancer agents. * Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.
Conditions
- Clear Cell Renal Cell Carcinoma
- Ovarian Cancer
- Other Advanced Solid Tumors
Interventions
QLS5133; Lenvatinib mesylateDrug
QLS5133: Intravenous infusion, Q3W; Lenvatinib mesylate: Oral, once daily
QLS5133; QL2107; Lenvatinib mesylateDrug
QLS5133 and QL2107: Intravenous infusion, Q3W; Lenvatinib mesylate: Oral, once daily
QLS5133; BevacizumabDrug
Intravenous infusion,Q3W
QLS5133; Platinum; BevacizumabDrug
Intravenous infusion,Q3W
QLS5133; Olaparib; BevacizumabDrug
Olaparib is oral; all others are intravenous infusion,Q3W
QLS5133; QL2107; BevacizumabDrug
Intravenous infusion,Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib Outcome 1:Incidence and severity of adverse events and serious adverse eventsTime frame: up to 2 years
- Phase Ib Outcome 2:Maximum tolerated dose (MTD)Time frame: 28 days
- Phase Ib Outcome 3:Recommended Phase 2 Dose (RP2D)Time frame: up to 2 years
- Phase II outcome 1:Objective response rate (ORR) (Arms 1B, 2B, 3B-3, 4B, 6B)Time frame: up to 2 years
- Phase II outcome 2:Progression-free survival (PFS) (Arms 3B-1, 3B-2, and 5B)Time frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.